Key statistics
On Friday, Rhythm Pharmaceuticals Inc (1RV:STU) closed at 54.16, -13.32% below its 52-week high of 62.48, set on Nov 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 54.16 |
---|---|
High | 54.16 |
Low | 54.16 |
Bid | 53.35 |
Offer | 54.74 |
Previous close | 54.32 |
Average volume | 6.20 |
---|---|
Shares outstanding | 61.46m |
Free float | 57.57m |
P/E (TTM) | -- |
Market cap | 3.64bn USD |
EPS (TTM) | -4.31 USD |
Data delayed at least 15 minutes, as of Feb 14 2025.
More ▼
Announcements
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
- Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
- Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old
- Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
- Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
More ▼